Publications

Viswanathan Lab Publications

Selected Publications

Since 2019:

  1. Achom, M. et al. A genetic basis for sex differences in Xp11 translocation renal cell carcinoma. Cell 0, (2024).
  2. Sadagopan, A. et al. Somatic XIST activation and features of X chromosome inactivation in male human cancers. Cell Syst 13, 932-944.e5 (2022).
  3. Tang, S. et al. A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer. Cell Rep 38, 110417 (2022).
  4. Bakouny, Z. et al. Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Rep 38, 110190 (2022).

Pre-2019:

  1. Viswanathan, S. R. et al. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell 174, 433-447.e19 (2018).
  2. Viswanathan, S. R. et al. Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome  1p loss in cancer. Nat Genet 50, 937–943 (2018).
  3. Viswanathan, S. R., Daley, G. Q. & Gregory, R. I. Selective blockade of microRNA processing by Lin28. Science 320, 97–100 (2008).
  4. Viswanathan, S. R. et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 41, 843–848 (2009).

Preprints (not yet published)

 
Garinet S, Semaan K, Li J, Sadagopan A, Canniff J, Phillips N, Konda P, Zhang Z, Klega K, Panday M, Savignano H, Davidsohn MP, Lyons K, Medda A, Khanna P, Achom M, Fortunato BJ, Nawfal R, Chehade REH, O’Toole J, Horst J, Freeman D, Trowbridge R, Chau CH, Figg WD, Berchuck JE, Crompton BD, Seo JH, Choueiri TK, Freedman ML, Baca SC, Viswanathan SR. Detection and monitoring of translocation renal cell carcinoma via plasma cell-free epigenomic profiling [Internet]. bioRxiv; 2025 [cited 2025 Sep 5]. p. 2025.08.31.673338. Available from: https://www.biorxiv.org/content/10.1101/2025.08.31.673338v1
 
 
Konda P, Weiss CN, Cui Y, Matar S, Wang J, Nabil YL, Deodhar R, Li J, Horst J, Camp SY, Sheshdeh AB, Hecht JL, Einstein DJ, Rustagi Y, Nag A, Thorner AR, Zhang CZ, Van Allen EM, Signoretti S, Choueiri T, Viswanathan SR. Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma [Internet]. Genomics; 2025 [cited 2025 Sep 5]. Available from: http://biorxiv.org/lookup/doi/10.1101/2025.08.28.672849
 
 
Gupta S, Khanna P, Saad E, Saliby RM, AbuHammad S, Li J, Li B, Konda P, Ahmed UA, Sadagopan A, Xu Q, Bakouny Z, Xu W, Srinivasan R, Choueiri TK, Viswanathan SR. Dual Inhibition of CDK4/6 and mTORC1 Establishes a Preclinical Strategy for Translocation Renal Cell Carcinoma [Internet]. Cancer Biology; 2025 [cited 2025 Sep 5]. Available from: http://biorxiv.org/lookup/doi/10.1101/2025.07.11.663903 PMCID: PMC12312178
 
 
Thapa DR, Deodhar R, Skepner A, Konda P, Zhou M, Bluck J, Pichlo C, Cui Y, Stocker P, Khanna P, Li J, Tsai JM, Leed A, Gould S, Alimova M, Friedrich D, Cheah JH, Rupaimoole R, Guicherit O, Viswanathan SR. Phenotypic screening converges on CDK9 inhibition as a therapeutic strategy in translocation renal cell carcinoma [Internet]. Cancer Biology; 2025 [cited 2025 Sep 5]. Available from: http://biorxiv.org/lookup/doi/10.1101/2025.08.25.672235 PMCID: PMC12407813
 
 
Li B, Sadagopan A, Li J, Wu Y, Cui Y, Konda P, Weiss CN, Choueiri TK, Doench JG, Viswanathan SR. A framework for target discovery in rare cancers. bioRxiv. 2024 Nov 20;2024.10.24.620074. PMCID: PMC11527139

Complete Publications